OAM
ORIC icon

Oxford Asset Management’s Oric Pharmaceuticals ORIC Stock Holding History

Oxford Asset Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,638
Closed -$161K – 659
2025
Q4 		$161K Buy
+19,638
New +$226K 0.06% 407
2024
Q2 		– Sell
-11,689
Closed -$161K – 387
2024
Q1 		$161K Buy
+11,689
New +$139K 0.17% 204

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Oxford Asset Management's ORIC Position: Q1 2026 in Review

Oxford Asset Management sold out of Oric Pharmaceuticals (ORIC) in Q1 2026, closing a stake of 19,638 shares — an estimated $161K sold.

Oxford Asset Management first reported a position in ORIC in Q1 2024 and held it in 2 quarters. The position peaked at $161K in Q1 2024. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Oxford Asset Management reported no remaining Oric Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Oxford Asset Management sold 19,638 Oric Pharmaceuticals shares in Q1 2026, an estimated $161K.
  • Oxford Asset Management first reported a position in Oric Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Oxford Asset Management's Oric Pharmaceuticals position peaked at $161K in Q1 2024.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Oxford Asset Management's 13F filing for Q1 2026, filed 15 May 2026.